What Orthofix SpinalStim is used for
The Orthofix SpinalStim bone growth stimulator is a prescription, noninvasive device that delivers pulsed electromagnetic field therapy, commonly called PEMF, around a spinal fusion site. Its FDA-labeled use is specific. SpinalStim is not a general treatment for back pain. It is indicated as an adjunct to spinal fusion to increase the probability of fusion success, and as a nonoperative treatment option for salvage of a failed spinal fusion when at least nine months have passed since the last surgery. In clinical practice, that means it may be considered when a surgeon wants additional support for bone healing after fusion, or when a previous fusion has not united as expected.
For readers comparing technologies in the spinal devices category, SpinalStim should not be grouped with implants, screws, cages, biologic graft materials, or neurostimulation systems. It is worn externally, does not require implantation, and is intended to support the bone-healing environment rather than provide mechanical stabilization of the spine.
How PEMF bone growth stimulation fits into spinal fusion care
Spinal fusion depends on several connected factors: preparation of the bone surfaces, stable fixation, graft material or biologic substrate, patient biology, and postoperative behavior. A bone growth stimulator does not replace those fundamentals. PEMF therapy is used as an adjunctive signal that may help stimulate cellular activity involved in bone formation.
The device includes a control unit and treatment coils built into a wearable external frame. According to Orthofix patient labeling, the coils are positioned over the treatment area so the PEMF field can reach the fusion site. The current U.S. patient manual describes the unit as lightweight, adjustable, portable, rechargeable, and equipped with display and audible indicators to help users track therapy time and compliance.
This distinction is important because the phrase “spinal stim” is sometimes confused with spinal cord stimulation. They are different categories. Spinal cord stimulators are neuromodulation systems, usually trialed or implanted, and are intended to alter pain signaling. SpinalStim is an external bone growth therapy device used under physician prescription to support fusion biology.
Approved uses and boundaries of the device
FDA approval language and manufacturer prescribing statements are the clearest references for understanding what the device is designed to do. The SpinalStim indication is tied to spinal fusion support and failed spinal fusion salvage. It should not be described as a general fracture device, a consumer wellness PEMF product, or a treatment that guarantees fusion.
| Device or category | Primary technology | Relevant labeled role | Key distinction |
|---|---|---|---|
| Orthofix SpinalStim | PEMF | Adjunct to spinal fusion; nonoperative salvage of failed spinal fusion after a minimum nine months since the last surgery | Focused on spinal fusion support and failed fusion salvage |
| Orthofix CervicalStim | PEMF | Adjunct to cervical fusion surgery in patients at high risk for non-fusion | Cervical-specific high-risk fusion indication |
| Orthofix PhysioStim | PEMF | Established traumatic nonunion, excluding vertebrae and flat bones | Non-spinal nonunion device, not for vertebral nonunion |
| Orthofix AccelStim | Ultrasound | Selected nonunion and fresh fracture indications, excluding skull and vertebra for nonunion treatment | Uses ultrasound rather than PEMF |
The comparison shows why precise product naming matters. Patients may use the broad phrase “bone growth stimulator,” but the labeled indication changes by device, body region, technology, and risk profile. A lumbar fusion patient, a high-risk cervical fusion patient, and a patient with a tibial nonunion may all be discussing bone stimulation, but not necessarily the same product or approved use.
What the evidence says, and where caution is needed
The clinical literature on PEMF in spine fusion includes older randomized work, post-market studies, retrospective evaluations, and analyses of patients with risk factors for pseudarthrosis. The evidence is not uniform across lumbar fusion, cervical fusion, revision settings, and failed fusion salvage, so broad claims should be avoided.
A frequently cited American Journal of Orthopedics study published in 2004 evaluated 100 patients with symptomatic pseudarthrosis established more than nine months after lumbar fusion. Patients used PEMF for at least 90 days, and solid fusion was reported in 67% of patients. The study supports the concept of nonoperative salvage in selected failed lumbar fusion cases, but it was not a modern randomized trial and should be read with that limitation in mind.
More recent spine literature has examined PEMF use in patients with risk factors for pseudarthrosis, including nicotine use, diabetes, osteoporosis, prior failed fusion, multilevel surgery, and multiple concurrent risks. An International Journal of Spine Surgery article reported an 88.0% fusion rate at 12 months among 142 evaluable patients receiving adjunctive PEMF after lumbar fusion, with similar rates across groups with one or multiple risk factors. A Journal of Spine Surgery publication in 2026 described a retrospective controlled evaluation of PEMF following lumbar spinal surgery, with higher reported fusion success in the treated group than in the control group. Because some studies include industry authors or post-market designs, the responsible interpretation is that PEMF may be useful as an adjunct in selected higher-risk fusion populations, while treatment decisions remain specific to the surgeon and patient.
The FDA’s public materials on noninvasive bone growth stimulators also place these products in a regulated medical-device context. Orthofix’s PMA-related records for P850007 include PEMF bone growth stimulator technology, and SpinalStim labeling defines the approved use. This regulatory history is more useful than marketing shorthand because it connects the device to specific indications, warnings, and use expectations.
Who may be considered for SpinalStim
Physicians may consider bone growth stimulation when a patient has factors that make fusion biology less predictable. Orthofix educational materials list common risk factors such as smoking or tobacco use, diabetes, obesity, multilevel fusion, medications that deplete bone, higher-grade spondylolisthesis, and allograft use. Other clinical factors can also matter, including revision surgery, bone quality, nutritional status, adherence to restrictions, and the mechanical demands on the fusion construct.
Those factors do not mean every patient automatically needs a stimulator. A single-level fusion in a healthy nonsmoker carries a different risk profile from a multilevel revision fusion in a patient with osteoporosis and nicotine exposure. The device is typically prescribed by the treating physician after reviewing the surgical plan, imaging, health history, and payer requirements.
For failed fusion, the nine-month timing in the labeled indication is important. Early postoperative pain or slow radiographic maturation does not necessarily mean established pseudarthrosis. Fusion assessment may require serial imaging and clinical judgment. Patients should not view SpinalStim as a quick fix for any postoperative symptom; it is a therapy linked to fusion biology and physician diagnosis. See also: Implants.
Daily use, compliance, and practical expectations
The practical question many patients ask first is how long they need to wear the device each day. Orthofix’s current patient materials state that SpinalStim has a minimum daily treatment time of two hours per day, while the physician may prescribe a specific schedule based on patient need. The device can generally be worn over clothing or an orthopedic brace. Treatment sessions may be split, and manufacturer materials recommend sessions of at least 60 minutes.
Compliance is not just a convenience issue. Orthofix labeling notes that inconsistent users in premarketing data, defined as patients averaging less than two hours per day, had success rates similar to placebo users. The device display includes compliance-related information, and physicians may review usage during follow-up visits.
Treatment duration varies. Orthofix patient information states that many patients wear a bone growth therapy device for three to nine months, but the actual period depends on healing progress, risk factors, compliance, and the surgeon’s assessment. Follow-up imaging and clinical evaluation remain central. A patient should not stop using the device early simply because pain improves, and persistent pain should not automatically be interpreted as device failure.
Safety issues and patient questions to raise before use
SpinalStim is external and noninvasive, but it is still a prescription medical device with defined limits. The manufacturer’s prescribing statement says cardiac pacemakers may be adversely affected by PEMF exposure and lists implanted cardiac pacemaker use as a contraindication. Orthofix labeling also states that safety and effectiveness have not been established for individuals lacking skeletal maturity, and that safety during pregnancy or nursing has not been established.
Reported adverse effects in labeling include rare reversible minor discomfort, such as the device feeling cumbersome or uncomfortable, minor tingling or pain, minor skin rash, insomnia, fainting, nausea or diarrhea, and polymenorrhea. Patients with implanted electronic devices, pregnancy concerns, skin sensitivity, difficulty wearing the unit, or questions about imaging procedures should ask the prescribing physician for device-specific instructions before use.
Patients should also clarify payer and workflow issues early. Bone growth stimulators are often coordinated through a prescription, device fitting, patient education, and insurance authorization process. The treating office, device representative, and insurer may each have a role, but the clinical decision should remain anchored in the surgeon’s assessment of fusion risk and indication.
Frequently asked questions
Is Orthofix SpinalStim the same as a spinal cord stimulator?
No. SpinalStim is an external PEMF bone growth stimulator used to support spinal fusion healing. A spinal cord stimulator is a neuromodulation system used for pain management and typically involves implanted or trial leads. The names sound similar, but the purposes and technologies are different.
How soon after fusion surgery is it used?
Timing is determined by the surgeon and prescription. SpinalStim is labeled as an adjunct to spinal fusion and also as a nonoperative salvage treatment for failed spinal fusion when at least nine months have elapsed since the last surgery. The adjunctive use and failed-fusion use should not be confused.
Does SpinalStim guarantee that a fusion will heal?
No. The device is intended to increase the probability of fusion success when used appropriately, but it does not guarantee healing. Fusion outcome can be influenced by surgical technique, fixation, graft strategy, smoking, diabetes, bone quality, number of levels fused, medication use, and patient compliance.
Can patients feel PEMF treatment while wearing the device?
Orthofix patient materials state that users typically do not feel the PEMF therapy from SpinalStim. The device display and timer are used to confirm that treatment is being delivered. If an error code appears or the display does not behave as expected, patients should contact the support channel provided with the device.
What source materials support these facts?
This article is based on publicly available FDA PMA information, Orthofix SpinalStim prescribing statements and patient manual materials, and peer-reviewed spine literature, including studies published in American Journal of Orthopedics, International Journal of Spine Surgery, and Journal of Spine Surgery. The information is educational and should not replace advice from a licensed physician.